Clinical Trial Update: CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy [Phase 1]

View source ↗

Summary

A completed Phase 1 trial assessing a CCR2-targeted PET imaging agent to visualize pancreatic tumors and predict response to standard treatment and CCR2-directe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CCR2 PET imaging agent
• CCR2-targeted therapy

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED